Human Metabolome Technologies, Inc. (JP:6090)
:6090
Want to see JP:6090 full AI Analyst Report?
6090 Stock Chart & Stats
¥715.00
¥1.00(0.16%)
At close: 4:00 PM EST
¥715.00
¥1.00(0.16%)
Day’s Range― - ―
52-Week Range¥626.00 - ¥869.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.25K
Market Cap
¥3.71B
Enterprise Value¥2.13B
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥110.47M
Price to Earnings (P/E)7.8
Beta0.24
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.35%
Share Statistics
EPS (TTM)43.61
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.36
Price to Sales (P/S)3.09
P/FCF Ratio19.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Metabolomics TechnologyHuman Metabolome Technologies' proprietary metabolomics platforms underpin a durable competitive advantage by creating specialized capabilities and validated workflows. This supports long-term service relationships with pharma, biotech, food and academic customers and raises switching costs for clients.
Strong Balance SheetVery low leverage and a strong equity ratio give the company financial flexibility to fund R&D, expand lab capacity, or withstand cyclical slowdowns without heavy refinancing. A solid ROE indicates efficient capital use supporting sustainable investment returns.
High And Sustainable MarginsConsistently high gross and healthy net margins reflect differentiated services and pricing power in specialized analytical work. Strong margin structure supports long-term cash generation, reinvestment in technology, and resiliency against cost swings.
Bears Say
Negative Revenue TrendSustained or recurring top-line decline undermines scalability: with falling revenue, even strong margins yield less absolute profit and cash. Continued negative growth constrains the firm’s ability to leverage fixed costs and to justify incremental investments in capacity or sales.
Cash Flow VolatilityModerate conversion of net income to operating cash and a prior negative FCF year indicate cash generation can be uneven. Volatile free cash flow complicates funding of capex, R&D and shareholder returns, raising execution and financing risk over the medium term.
Small Organizational ScaleA small headcount and boutique scale limit commercial reach, capacity expansion and redundancy. This raises operational concentration risk, slows large contract capture and makes sustaining growth or rapid scaling more challenging versus larger diagnostics service providers.
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥626.00 and its highest was ¥869.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥3.71B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 83 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on May 13, 2026. The company reported ¥21.61 earnings per share for the quarter, beating the consensus estimate of N/A by ¥21.61.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Overvalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥15 which represents an annual dividend yield of 2.35%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥21.61 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.147%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. (6090) is a biotechnology company specializing in the analysis of human metabolites to advance the understanding of human health and disease. The company operates primarily in the life sciences sector, offering a range of services that include metabolomics research, biomarker discovery, and diagnostic development. Its core products include advanced analytical platforms and proprietary software for metabolomic data analysis, catering to pharmaceutical companies, academic institutions, and healthcare providers.
Technical Analysis
BML
―
Shin Nippon Biomedical Laboratories, Ltd.
―
Cosmo Bio Co., Ltd.
―
Kainos Laboratories, Inc.
―
Perseus Proteomics, Inc.
―